Connect Biopharma Holdings Limited (NASDAQ:CNTB) Shares Bought by Callan Capital LLC

Callan Capital LLC raised its holdings in Connect Biopharma Holdings Limited (NASDAQ:CNTB) by 91.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 80,000 shares of the company’s stock after acquiring an additional 38,177 shares during the quarter. Callan Capital LLC owned 0.14% of Connect Biopharma worth $110,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CNTB. Catalina Capital Group LLC acquired a new stake in shares of Connect Biopharma in the fourth quarter valued at about $66,000. Choreo LLC acquired a new stake in shares of Connect Biopharma during the 4th quarter valued at approximately $204,000. Finally, BML Capital Management LLC lifted its position in shares of Connect Biopharma by 2.4% during the 3rd quarter. BML Capital Management LLC now owns 2,093,232 shares of the company’s stock valued at $3,014,000 after acquiring an additional 49,984 shares during the period. Institutional investors and hedge funds own 58.72% of the company’s stock.

Connect Biopharma Stock Up 1.2 %

Shares of CNTB stock opened at $0.87 on Monday. The stock has a fifty day moving average price of $1.04 and a 200 day moving average price of $1.13. Connect Biopharma Holdings Limited has a 1 year low of $0.77 and a 1 year high of $2.66.

Connect Biopharma Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.